FDA Expectations for AI/ML Software Validation in GxP Environments

In September 2022, FDA finalized its Computer Software Assurance (CSA) guidance — the agency’s first meaningful rethink of software validation philosophy since a 1987 general principles document. That shift from exhaustive IQ/OQ/PQ documentation to “critical thinking and risk-based testing” was a significant pivot. But it arrived just as pharmaceutical manufacturers started deploying something the guidance authors almost certainly hadn’t anticipated at scale: machine learning models embedded directly into GxP workflows.

Two years later, regulated manufacturers are running AI-driven batch disposition tools, ML-based chromatography anomaly detection, and LLM-assisted CAPA drafting — all within quality systems where 21 CFR Part 11 and 21 CFR Part 211 still apply in full. The questions I hear most often from quality directors aren’t philosophical. They’re operational: What does FDA actually expect when you validate an AI model that learns from new data? What does “verified” mean when the system’s behavior changes after retraining?

Those aren’t questions you can answer by rereading the CSA guidance a second time. This post works through the specific compliance gaps that AI/ML deployments create in GxP environments, and what a defensible validation strategy looks like given where FDA’s thinking actually stands today.

The Validation Framework AI/ML Systems Were Not Built For

Traditional Computer System Validation (CSV) follows a reasonably linear path: define user requirements, qualify installation and operation, validate performance, lock the system, change-control everything thereafter. That model works well for static software — an LIMS with defined database fields, a spectrophotometer’s embedded firmware, an ERP module with fixed business logic.

AI/ML systems break this model at the “lock it and change-control it” step. A supervised learning model retrained monthly on new manufacturing data is, from a CSV perspective, a system that generates a change deviation approximately every 30 days. A reinforcement learning agent optimizing fermentation parameters has no stable “validated state” in any traditional sense. FDA’s 2022 CSA guidance says testing “should be commensurate with risk” — but it doesn’t tell you what to do when the system’s risk profile shifts as the model drifts on new production data.

GAMP5 Second Edition, published by ISPE in January 2022, introduced updated Category 5 guidance that acknowledges “complex and novel” software. But even its revised framework assumes you can characterize the software’s behavior set at a defined point in time. For models retrained on streaming data, that assumption doesn’t hold. The validation community is still catching up, and that gap falls on quality teams to navigate without clear regulatory direction.

What FDA’s CSA Guidance Changes — and What It Doesn’t

FDA’s CSA guidance retired the prescriptive deliverable stack for production and quality system software. Gone — at least as mandatory requirements — are the rigid IQ/OQ/PQ trilogy, the expectation that every parameter change triggers a full revalidation cycle, and the culture of validation-by-documentation weight. What replaced them is a risk-based testing philosophy centered on three questions: Does the software affect product quality? What is the likelihood and severity of failure? What testing is proportionate to that risk?

That framework is genuinely better suited to AI/ML validation in principle. In practice, applying “critical thinking” to a transformer-based anomaly detection model requires expertise that most quality teams don’t have in-house, and that most validation SOPs don’t encode. CSA gives you the latitude to do this right — it doesn’t give you a roadmap.

More pointedly, the CSA guidance doesn’t resolve the core tension between continuous model improvement and GxP system lock. FDA addressed AI/ML more directly in its Artificial Intelligence Action Plan (published January 2021) and through its work on Predetermined Change Control Plans (PCCPs) — a mechanism developed for AI/ML Software as a Medical Device (SaMD) under 21 CFR Part 820. But for pharmaceutical manufacturing software governed by 21 CFR Part 211 and 21 CFR Part 11, FDA has published no equivalent PCCP framework. That regulatory gap is real, and it’s where most AI validation programs stall.

Four Validation Challenges Specific to AI/ML in GxP

1. Defining the Validated State for a Retrained Model

With traditional software, the validated state is the released version at a specific patch level. With a retrained ML model, you need to define what constitutes a “new” system requiring revalidation versus a routine update covered under a pre-approved change control procedure. FDA’s expectation — based on CSA language and on warning letter observations around automated system changes — is that this boundary exists in documented form before deployment, not after a deviation report forces the question.

The defensible approach: define your model’s validation boundary by performance thresholds rather than by code version. If a retrained model’s performance on your held-out validation dataset stays within ±2% of baseline accuracy on critical quality attribute predictions, that’s a pre-approved continuous improvement activity. If performance degrades beyond that threshold, or if the training dataset composition changes materially, the change triggers a formal revalidation. That logic needs to be in your validation master plan before the first model goes live.

2. Audit Trail Requirements Under 21 CFR Part 11

21 CFR Part 11 requires audit trails for any electronic system that creates, modifies, or transmits records used in GMP decisions. For an AI model, this raises a non-trivial question: what constitutes the “record”? The model’s prediction output? The model weights at the moment of inference? The training dataset version? The feature engineering pipeline used to transform raw inputs?

FDA hasn’t published explicit Part 11 guidance for ML inference records, but the agency’s 2018 Data Integrity and Compliance With Drug CGMP guidance makes the intent clear. You need to be able to reconstruct, for any GMP-relevant decision supported by an AI output, exactly what the model saw, what it predicted, and which model version was running at that moment. That means versioning model artifacts — not just the application code, but the weights file, the preprocessing pipeline, and the calibration parameters — with the same rigor you’d apply to any LIMS configuration change.

3. Explainability as a De Facto Compliance Requirement

FDA hasn’t mandated explainable AI (XAI) for pharma manufacturing software the way it has signaled for AI/ML medical devices. But it doesn’t need to. The existing batch record requirements under 21 CFR Part 211.192 already require that records be “reviewed by the quality control unit to determine compliance with written specifications and standards.” If a quality professional cannot interpret why a model flagged a batch for review, they cannot meaningfully fulfill that review obligation — regardless of what the AI output says.

This isn’t purely theoretical. We’ve seen audit observations where FDA investigators cited an inability to “demonstrate understanding of the automated system’s decision logic” — language that maps directly to 21 CFR Part 211.68 requirements for automatic, mechanical, and electronic equipment. For black-box models making or supporting critical quality decisions, the explainability gap is a genuine compliance liability, and it needs to be addressed during design — not after an observation.

4. Supplier Qualification for AI Components and Dependencies

Many AI/ML systems in GxP environments depend on third-party foundation models, cloud-based ML APIs, or open-source frameworks whose version lifecycles are entirely outside your change control system. PyTorch releases a new version; your training pipeline updates a dependency automatically; your validation now covers behavior you haven’t tested. Under FDA’s supplier qualification expectations — rooted in 21 CFR Part 211.84 and codified in GAMP5’s supplier assessment guidance — you’re responsible for these upstream components.

The practical fix is explicit dependency pinning combined with a vendor risk assessment that formally covers AI/ML components. For cloud-based AI services, your supplier qualification package needs to address FDA data integrity requirements — including data sovereignty, audit log access, change notification SLAs, and system availability commitments — as formally as you’d qualify any other GxP service provider. A vendor who can’t provide those commitments in writing isn’t a qualified GxP supplier, regardless of how capable their model is.

Building a Compliant AI Validation Strategy: Where to Start

Given the gaps in current guidance, a defensible AI validation program in a regulated environment needs to accomplish three things simultaneously.

Anchor to existing requirements. 21 CFR Part 11, 21 CFR Part 211, and the CSA guidance still define the floor. Any AI system that touches GMP records, controls manufacturing processes, or generates data used in batch release decisions is subject to these requirements without exception. Start your validation strategy by mapping the AI system’s data flows against those specific CFR citations — before selecting a validation methodology or writing a single protocol.

Build a change control strategy for model evolution. Define, in writing and before deployment, the criteria that distinguish a continuous improvement update from a revalidation-triggering change. Tie those criteria to measurable performance indicators on a representative validation dataset, not to subjective assessments of whether the “underlying logic” changed. That documented logic is what an investigator will ask to see first.

Document intent, not just outputs. FDA investigators reviewing AI validation packages aren’t primarily looking for test result summaries — they’re looking for evidence that your quality team understood what they were deploying and why. A well-reasoned risk assessment that explains why a particular model architecture was chosen, what its failure modes are, and how those failure modes are mitigated will do more for your inspection readiness than 400 pages of IQ/OQ/PQ protocols that don’t address the model’s actual behavior.

Regulatory compliance consulting services that specialize in AI/ML validation remain a niche market — most traditional CSV consultants don’t have hands-on ML experience, and most ML engineers don’t know 21 CFR Part 11 from 21 CFR Part 820. That skills gap is where the majority of regulated organizations get stuck, and closing it is genuinely the highest-leverage investment a quality team can make before deploying AI in a GxP environment.

Written by Sam Sammane, Founder & CEO, Aurora TIC | Founder, Qalitex Group. Learn more about our team

Reserve early access to our AI audit tools Contact us

Related from our network

• LIMS Data Integrity and ISO 17025 Compliance for AI-Enabled Labs — How US testing laboratories are hardening their quality systems to support AI-assisted analysis under accreditation requirements.
• GMP Software Validation for Canadian Pharmaceutical Manufacturers — How Health Canada’s expectations for computerized systems align — and diverge — from FDA’s CSA framework.